Related Experiment Video

Updated: May 29, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

[Monoclonal antibodies to type A, B, E and F botulinum neurotoxins]

S G Abbasova, N V Ruddenko, A Iu Gorokhovatskiĭ

    Bioorganicheskaia Khimiia
    |September 9, 2011
    PubMed

    Insights

    New monoclonal antibodies effectively detect and neutralize botulinum neurotoxins (BoNTs) types A, B, E, and F. These antibodies show promise for diagnosing and treating botulism, particularly BoNT/A.

    Area of Science:

    • Immunology
    • Toxicology
    • Biotechnology

    Background:

    • Botulinum neurotoxins (BoNTs) are highly toxic substances causing botulism.
    • Accurate detection and therapeutic neutralization of BoNTs are critical for public health.

    Purpose of the Study:

    • To generate and characterize mouse monoclonal antibodies against BoNT types A, B, E, and F.
    • To develop sensitive sandwich-ELISA assays for quantitative BoNT detection.
    • To evaluate the therapeutic potential of specific antibodies against BoNT/A.

    Main Methods:

    • Generation and characterization of mouse monoclonal antibodies against BoNTs A, B, E, and F.
    • Development of sandwich-ELISA assays for toxin quantification.
    • In vivo neutralization assays using specific antibodies (BNTA-4.1 and BNTA-9.1) against BoNT/A.

    Main Results:

    • Monoclonal antibodies were generated that recognize BoNTs in their natural complex.
    • Sandwich-ELISA assays achieved detection limits as low as 0.1 ng/ml (BoNT/E).
    • Assays successfully quantified BoNTs in food samples (canned meat and vegetables).
    • Antibodies BNTA-4.1 and BNTA-9.1 demonstrated in vivo neutralizing activity against BoNT/A.
    • BNTA-4.1 binds the light chain, while BNTA-9.1 binds the heavy chain of BoNT/A.

    Conclusions:

    • Developed sensitive and specific assays for detecting BoNT types A, B, E, and F.
    • Identified monoclonal antibodies (BNTA-4.1 and BNTA-9.1) with significant neutralizing capacity against BoNT/A.
    • These antibodies are promising candidates for developing humanized therapeutics for botulism treatment.

    More Related Videos

    Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays12:25

    Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

    Published on: March 3, 2014

    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors14:10

    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

    Published on: November 14, 2014

    Related Concept Videos

    Botulism01:22

    Botulism

    Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
    Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

    Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

    Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
    The binding of dantrolene to the RYR1...
    Bacterial Toxins01:12

    Bacterial Toxins

    Bacterial toxins are sophisticated virulence factors that enable pathogenic bacteria to interact with, invade, and damage host tissues. These toxins fall broadly into two types: protein exotoxins, which are secreted into the environment and target specific host receptors, and lipopolysaccharide endotoxins, which are structural components of the bacterial outer membrane released primarily during bacterial lysis or membrane shedding. Exotoxins generally act more selectively, binding to cell...
    Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

    Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

    Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
    Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
    Tetanus01:29

    Tetanus

    Tetanus is a life-threatening neurological disorder characterized by persistent muscle contractions and spastic paralysis. It is caused by Clostridium tetani, a motile, Gram-positive, rod-shaped, obligate anaerobe. These bacteria produce terminal endospores, giving them a distinctive “lollipop” or “tennis-racket” appearance. They thrive in anaerobic environments, such as those found in deep puncture wounds.Once introduced into the body, the spores germinate into vegetative cells. These cells...
    Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

    Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

    Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
    Although all competitive neuromuscular blockers are designed...